
Morgan Stanley (MS) is poised to report Q2 earnings on July 16, with analysts projecting year-over-year growth to $2.01 EPS and $16.04 billion in revenue. The stock gained 1.1% to $143.09, reflecting anticipation and recent analyst activity, including a Keefe, Bruyette & Woods upgrade to Outperform with a $160 price target, alongside other firms maintaining varied ratings but mostly higher price targets, signaling mixed but generally constructive sentiment ahead of the release.
Morgan Stanley (MS) is positioned for a strong second-quarter earnings report on July 16, with analyst consensus projecting significant year-over-year growth. Expectations are for quarterly revenue to rise to $16.04 billion from $15.02 billion and for EPS to increase to $2.01 from $1.82. This positive outlook is reflected in the stock's recent 1.1% gain to $143.09 and a moderately positive sentiment score of 0.65. Analyst ratings present a divided but recently improving picture. A significant bullish catalyst is the recent upgrade from Keefe, Bruyette & Woods to "Outperform" with a new price target of $160, a notable increase from $127 issued by a highly-rated analyst. However, this optimism is tempered by several other major firms, including Wells Fargo, Citigroup, and Goldman Sachs, which maintain "Neutral" or "Equal-Weight" ratings. While these firms also raised their price targets, some targets remain below the current stock price, suggesting they see the company as more fully valued. The sale of an ownership stake in TigerGenCo is a routine portfolio management event for its infrastructure funds and is unlikely to be a material driver for the upcoming results.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment